Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quaratusugene ozeplasmid
- Development stage
- Phase 2
- Lead developer
- Genprex
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Quaratusugene ozeplasmid** is Genprex's investigational, systemic non-viral **TUSC2 gene-replacement therapy** for lung cancer. It comprises a plasmid encoding the tumor-suppressor gene **TUSC2** encapsulated in positively charged lipid-based nanoparticles in a lipoplex formulation using the ONCOPREX Delivery System. Following intravenous administration, the product is intended to preferentially enter negatively charged tumor cells and restore TUSC2 expression, thereby inhibiting proliferative signaling, promoting apoptosis, and modulating antitumor immune activity. The program is in Phase 1/2 development in combination with osimertinib for EGFR-mutated non-small cell lung cancer and with atezolizumab as maintenance therapy for extensive-stage small cell lung cancer. ([genprex.com](https://www.genprex.com/technology/reqorsa/))
- Brand names
- Reqorsa
- Other names
- Quar Oze
02
Targets
TUSC2 (Tumor suppressor candidate 2)
Beyond the preview
Go deeper on quaratusugene ozeplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quaratusugene ozeplasmid.